Related Experiment Videos
Development of C-20 modified betulinic acid derivatives as antitumor agents
1The Program for Collaborative Research in Pharmaceutical Science and the Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 60612, USA.
Abstract:
Chemical modifications were performed on C-20 position of betulinic acid for a structure-activity relationship study. The evaluation of the compounds using human colon carcinoma HCT-116, human prostate adenocarcinoma PC3, and human melanoma cell lines M14-MEL, SK-MEL-2, and UACC-257 did not show any selective cytotoxicity towards melanoma cells. The results from both MTT reduction assay and SRB staining assay were comparable that no remarkable differences in cytotoxicity profile of the compounds were noticed. The C-20 position was found to be sensitive to the size and the electron density of the substituents in retaining the cytotoxicity of betulinic acid and was found to be undesirable position to derivatize.
Insights
Modifying betulinic acid at the C-20 position did not yield selective cytotoxicity against melanoma cells. This position is sensitive to substituent size and electron density, making it unsuitable for developing new anticancer drugs.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Betulinic acid is a natural triterpenoid with known anticancer properties.
- Structure-activity relationship (SAR) studies are crucial for optimizing drug candidates.
- Investigating modifications at specific positions of betulinic acid can reveal insights into its cytotoxic mechanism.
Purpose of the Study:
- To synthesize and evaluate novel betulinic acid derivatives modified at the C-20 position.
- To assess the selective cytotoxicity of these derivatives against various cancer cell lines, particularly melanoma.
- To understand how modifications at C-20 impact the biological activity of betulinic acid.
Main Methods:
- Chemical synthesis of betulinic acid derivatives with modifications at the C-20 position.
- Cytotoxicity assays including MTT reduction and SRB staining.
- Evaluation against human colon carcinoma (HCT-116), prostate adenocarcinoma (PC3), and melanoma (M14-MEL, SK-MEL-2, UACC-257) cell lines.
Main Results:
- The synthesized C-20 modified betulinic acid derivatives did not exhibit selective cytotoxicity towards melanoma cell lines.
- MTT reduction assay and SRB staining assay results were consistent, showing no significant differences in cytotoxicity profiles.
- Cytotoxicity was sensitive to the size and electron density of substituents at the C-20 position.
Conclusions:
- The C-20 position of betulinic acid is not a favorable site for derivatization to achieve selective anticancer activity, especially against melanoma.
- Modifications at C-20 negatively influence or do not enhance the cytotoxic potential of betulinic acid.
- Further SAR studies should explore alternative modification sites on the betulinic acid scaffold.